Cited 0 times in
Homeodomain-interacting protein kinase 1 (HIPK1) expression in breast cancer tissues
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 구자승 | - |
dc.contributor.author | 김승일 | - |
dc.contributor.author | 박병우 | - |
dc.contributor.author | 박세호 | - |
dc.contributor.author | 박지민 | - |
dc.contributor.author | 박형석 | - |
dc.contributor.author | 조정훈 | - |
dc.date.accessioned | 2014-12-19T17:00:05Z | - |
dc.date.available | 2014-12-19T17:00:05Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90593 | - |
dc.description.abstract | OBJECTIVE: This study investigated the incidence and clinical significance of homeodomain-interacting protein kinase 1 expression in breast cancer patients. METHODS: We investigated immunohistochemical homeodomain-interacting protein kinase 1 expression from tissue microarrays of 1032 patients. The association of homeodomain-interacting protein kinase 1 expression pattern, clinicopathologic factors and survival outcome was evaluated. Tumors with ≥10% stained cells were considered positive for homeodomain-interacting protein kinase 1. RESULTS: Non-cancerous breast tissue, pTis and pT1mic lesions did not show homeodomain-interacting protein kinase 1 expression at any sites. Of the 859 invasive tumors, 124 (14.4%) showed homeodomain-interacting protein kinase 1 expression with three different expression patterns: cytoplasmic (2.4%), nuclear (6.3%), and both cytoplasmic and nuclear (5.7%). Cytoplasmic homeodomain-interacting protein kinase 1-positive tumors showed distinctive features such as fewer nodal metastases, but were frequently Grade III, estrogen receptor-negative, progesterone receptor-negative, HER2-positive, highly proliferative and molecular apocrine tumors. No significant difference in clinicopathologic features was identified between negative and nuclear homeodomain-interacting protein kinase 1-positive tumors. Both cytoplasmic and nuclear HIPK1-positive tumors represent frequent small size, node negativity and moderately differentiated features. Survival was not significantly different by homeodomain-interacting protein kinase 1 expression patterns. CONCLUSIONS: Homeodomain-interacting protein kinase 1 expression was identified only in invasive breast cancer cells with three different patterns: cytoplasmic, nuclear, and both cytoplasmic and nuclear. Although the mechanism is not certain, the subcellular localization of HIPK1 expression is associated with tumor histopathologic characteristics and different functions. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | JAPANESE JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Biomarkers, Tumor/metabolism* | - |
dc.subject.MESH | Breast Neoplasms/epidemiology* | - |
dc.subject.MESH | Breast Neoplasms/metabolism* | - |
dc.subject.MESH | Breast Neoplasms/mortality | - |
dc.subject.MESH | Breast Neoplasms/pathology | - |
dc.subject.MESH | Cell Nucleus/metabolism | - |
dc.subject.MESH | Cytoplasm/metabolism | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Invasiveness | - |
dc.subject.MESH | Protein-Serine-Threonine Kinases/metabolism* | - |
dc.subject.MESH | Republic of Korea/epidemiology | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Tissue Array Analysis | - |
dc.title | Homeodomain-interacting protein kinase 1 (HIPK1) expression in breast cancer tissues | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pathology (병리학) | - |
dc.contributor.googleauthor | Byeong-Woo Park | - |
dc.contributor.googleauthor | Seho Park | - |
dc.contributor.googleauthor | Ja Seung Koo | - |
dc.contributor.googleauthor | Seung Il Kim | - |
dc.contributor.googleauthor | Ji Min Park | - |
dc.contributor.googleauthor | Jung Hoon Cho | - |
dc.contributor.googleauthor | Hyung Seok Park | - |
dc.identifier.doi | 23071292 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00198 | - |
dc.contributor.localId | A00658 | - |
dc.contributor.localId | A01475 | - |
dc.contributor.localId | A01524 | - |
dc.contributor.localId | A01685 | - |
dc.contributor.localId | A01753 | - |
dc.contributor.localId | A03906 | - |
dc.relation.journalcode | J01207 | - |
dc.identifier.eissn | 1465-3621 | - |
dc.identifier.pmid | 23071292 | - |
dc.subject.keyword | breast cancer | - |
dc.subject.keyword | homeodomain-interacting protein kinase 1 | - |
dc.subject.keyword | molecular apocrine tumor | - |
dc.contributor.alternativeName | Koo, Ja Seung | - |
dc.contributor.alternativeName | Kim, Seung Il | - |
dc.contributor.alternativeName | Park, Byeong Woo | - |
dc.contributor.alternativeName | Park, Se Ho | - |
dc.contributor.alternativeName | Park, Ji Min | - |
dc.contributor.alternativeName | Park, Hyung Seok | - |
dc.contributor.alternativeName | Cho, Jung Hoon | - |
dc.contributor.affiliatedAuthor | Koo, Ja Seung | - |
dc.contributor.affiliatedAuthor | Kim, Seung Il | - |
dc.contributor.affiliatedAuthor | Park, Byeong Woo | - |
dc.contributor.affiliatedAuthor | Park, Se Ho | - |
dc.contributor.affiliatedAuthor | Park, Ji Min | - |
dc.contributor.affiliatedAuthor | Park, Hyung Seok | - |
dc.contributor.affiliatedAuthor | Cho, Jung Hoon | - |
dc.contributor.affiliatedAuthor | 구자승 | - |
dc.citation.volume | 42 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1138 | - |
dc.citation.endPage | 1145 | - |
dc.identifier.bibliographicCitation | JAPANESE JOURNAL OF CLINICAL ONCOLOGY, Vol.42(12) : 1138-1145, 2012 | - |
dc.identifier.rimsid | 32857 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.